PBYI — Puma Biotechnology Share News
0.000.00%
Last trade - 00:00- $581.24m
- $487.34m
- $228.37m
Brief: Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
Puma Biotechnology Inc reports results for the quarter ended June 30 - Earnings Summary
Corrected: Puma Biotechnology lifts 2026 outlook as Q2 revenue rises on NERLYNX demand
Brief: Puma Biotechnology Q2 Adjusted EPS USD 0.2
Puma Biotechnology Inc expected to post earnings of 4 cents a share - Earnings Preview
US appeals court upholds win for AstraZeneca in Pfizer cancer drug patent fight (updated)
US appeals court upholds win for AstraZeneca in Pfizer cancer drug patent fight
Brief: Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule
Puma Biotechnology Q1 revenue falls on weaker NERLYNX sales; raises 2026 outlook
Brief: Puma Biotechnology Q1 Adjusted EPS USD -0.04
Brief: Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
Brief: Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
Puma Biotechnology Q4 product revenue rises to $59.9 mln
Brief: Puma Biotechnology Q4 Adjusted EPS USD 0.3
Brief: Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule
Brief: Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
Brief: Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
Puma Biotechnology Q3 product revenue falls
Brief: Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule